{"id":"NCT01818752","sponsor":"Amgen","briefTitle":"Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma","officialTitle":"A Randomized, Open-label Phase 3 Study of Carfilzomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-07-08","primaryCompletion":"2016-07-15","completion":"2016-11-04","firstPosted":"2013-03-26","resultsPosted":"2017-08-01","lastUpdate":"2019-08-26"},"enrollment":955,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Myeloma"],"interventions":[{"type":"DRUG","name":"Carfilzomib","otherNames":["Krypolis速"]},{"type":"DRUG","name":"Bortezomib","otherNames":["Velcade速"]},{"type":"DRUG","name":"Melphalan","otherNames":[]},{"type":"DRUG","name":"Prednisone","otherNames":[]}],"arms":[{"label":"Carfilzomib, Melphalan, Prednisone","type":"EXPERIMENTAL"},{"label":"Bortezomib, Melphalan, Prednisone","type":"ACTIVE_COMPARATOR"}],"summary":"The primary objective was to compare the progression-free survival of transplant ineligible patients newly diagnosed with multiple myeloma who were treated with carfilzomib, melphalan and prednisone (CMP) or with Velcade速 (bortezomib), melphalan and prednisone (VMP).","primaryOutcome":{"measure":"Progression-Free Survival (PFS)","timeFrame":"From randomization until the data cut-off date of 15 July 2016; median follow-up time for PFS was 21.6.and 22.2 months in the bortezomib and carfilzomib arms respectively.","effectByArm":[{"arm":"Bortezomib, Melphalan, Prednisone","deltaMin":22.1,"sd":null},{"arm":"Carfilzomib, Melphalan, Prednisone","deltaMin":22.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.1590"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":213,"countries":["United States","Argentina","Australia","Austria","Belgium","Bulgaria","Canada","China","Czechia","France","Germany","Greece","Hungary","Israel","Italy","Japan","Mexico","Netherlands","New Zealand","Poland","Romania","Russia","Singapore","South Korea","Spain","Switzerland","Taiwan","Turkey (T端rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["29991494","30819926","26771810"],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":198,"n":470},"commonTop":["Anaemia","Nausea","Pyrexia","Neutropenia","Diarrhoea"]}}